BioMarin Appoints Alexander Hardy President and CEO

San Rafael, CA, November 1, 2023 (PRNewswire) -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), today announced the appointment of Alexander Hardy as its new president and chief executive officer, effective December 1, 2023. Mr. Hardy, who is currently the CEO of Genentech, will also join BioMarin’s board of directors bringing his over 30 years of experience in global healthcare and biotechnology industries. Jean-Jacques Bienaimé, the outgoing chairman and CEO, will retire after leading the company for 18 years. Richard A. Meier, BioMarin’s lead independent director, will take over as chair of the board of directors.

Read full article here.